The Pharmacy Times® Oncology Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to oncology pharmacists.
July 18th 2025
The CRL states that the STARGLO data do not provide sufficient evidence to support the second-line indication in the US patient population.
Bemarituzumab Elicits Positive Overall Survival in FGFR2b-Positive First-Line Gastric Cancer
July 15th 2025The fibroblast growth factor receptor 2b (FGFR2b)-inhibiting bemarituzumab demonstrated improvements in overall survival and other key secondary end points compared with placebo in first-line gastric cancer.
Read More
ATOPP 2025: Navigating Biosimilar Adoption and Operational Strategies in Oncology
July 14th 2025Laura R. Bobolts, PharmD, BCOP, shares actionable strategies for oncology pharmacists to navigate biosimilar and 505(b)(2) drug implementation, manage payer and formulary complexities, and optimize cost-effective care delivery across oncology service lines.
Read More
ATOPP 2025: Pharmacy Innovation at the Intersection of EOM and Patient Access
July 10th 2025Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, FAPO, discusses how oncology pharmacists can lead value-based care efforts under the Enhanced Oncology Model (EOM) by improving care coordination, managing costs, aligning with performance metrics, and leveraging clinical data systems to enhance patient outcomes.
Read More
ATOPP 2025: Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, FAPO, Highlights Must-See Sessions
July 9th 2025Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, FAPO, discusses the value of the 2025 ATOPP Summit in advancing oncology pharmacy through collaboration, innovation, and actionable strategies aligned with evolving value-based care models.
Read More
Building a Sustainable Pharmacogenomics Program: A Pharmacist’s Perspective at Ochsner Health
July 7th 2025Serena Mitaly, PharmD, outlines how Ochsner Health is building a sustainable pharmacogenomics program by integrating clinical decision support tools into the EMR, educating providers, addressing reimbursement barriers, and expanding the role of PGx pharmacists in personalized medicine.
Read More
Sunvozertinib Approved by FDA as Oral Treatment of NSCLC With EGFR Exon 20 Insertion Mutations
July 7th 2025Sunvozertinib becomes the first and only targeted approval treatment for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
Read More
FDA Approves Linvoseltamab-gcpt for Treatment of Relapsed or Refractory Multiple Myeloma
Published: July 2nd 2025 | Updated: July 2nd 2025The treatment becomes the first approved BCMAxCD3 bispecific antibody with the potential to achieve biweekly or monthly dosing in patients with relapsed/refractory multiple myeloma.
Read More